Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

GYN > GYN Studies and PIs > Flashcards

GYN Studies and PIs Flashcards

1
Q

Adjuvant Ovary Treatment

A

Platinum chemo +/- Bev

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Maintenance Ovary Treatment

A

1) Obsv
2) Single agent bev
3) Single agent PARP
4) PARP + bev

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Hou et al key takeaways

A

1) 69 pts
2) 100% sens/spec - all + pts relapsed, all serially neg pts were disease free
3) CA-125 not prognostic for relapse

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

PARP Poster key takeaways

A

1) 45 pts
2) ctDNA was predictive of PARP response
3) all pts with rising ctDNA progressed and those serially neg had clinical benefit
4) CA-125 not associated with PFS

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

PAOLA-1

A

1) ENGOT study, PI Isabelle Ray-Coquard (France)
2) Maintenance escalation
3) Olaparib+bev vs bev

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

PRIMA

A

1) GOG/ENGOT study, PIs Antonio Martin (GEICO, Spain), Brad Monk (FL Cancer), Bhavna and Floor also authors
2) Maintenance escalation
3) Niraparib vs placebo

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

MONSTAR-ov

A

1) Japanese trial enrolling
2) Chemo/maintenance escalation
3) Adding bev to chemo and bev to niraparib for ctDNA+ pts

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

DUO-O

A

1) GOG/ENGOT study, PIs Carol Aghajanian (MSK), Philip Harter (Germany), pharma sponsor AZ
2) Chemo/Maintenance escalation
3) Adding Durva and olaparib to chemo/maintenance

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

GY-036

A

1) NRG study, PIs Rob Coleman (prev TX Oncology, CMO Vaniam Group), Tom Herzog (UCinncinati), Kathleen Moore (OK)
2) PARP duration 1 vs 2 yrs
3) Study discussion at ASCO GOG - need to discuss further

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

NeoPembrOV

A

1) ENGOT study, PI Isabelle Ray-Coquard (France)
2) Add Pembro to NAC, ACT and maintenance

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

MK-4830-002

A

1) Merck study, Lillian Siu (PMCC)
2) Add novel drug 4830 to NAC and ACT

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Ovary Areas of interest

A

1) Maintenance escalation and descalation
2) Surveillance and TOMR
3) Maintenance treatment monitoring and discontinuation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Stg I Endo ACT

A

1) HIR/HR go / no-go
2) XRT
3) XRT + chemo

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Endo surveillance

A

1) Based on physical exam
2) Limited CA-125/imaging
3) Most recurrences are local to pelvis and curable with XRT
4) Limits scope of TOMR

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Advanced/Metastatic Endo Treatment

A

1) Chemo
2) IO
3) IO + PARP +/- TKI

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Recio Early Endo Paper Take Aways

A

1) 101 pts
2) 100% NPV - all serially neg remained relapse free
3) 52% PPV for anytime + (median f/u ONLY 3 months!!)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

GY-020

A

1) NRG study, PI Floor Backes (OSU)
2) Stg I HIR dMMR EC
3) XRT vs XRT + Pembro
4) Emily contracting with NRG for samples

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

EMERGE-C

A

1) Pothuri NYU
2) HIR p53wt endo
3) ctDNA neg randomized to obsv vs XRT
4) Working on schema together

19
Q

KN-B21

A

1) Merck/GOG study; PI Brian Slomovitz (UMiami)
2) High risk endo
3) Adjuvant escalation
4) Adding Pembro to ACT
5) Negative study announced in May 2024
6) Can Signatera help find pts who will benefit (Imvigor)?

20
Q

DUO-E

A

1) AZ + GOG ; PI Shannon Westin (MDACC)
2) Advanced/recurrent endo
3) Maintenance escalation
4) Obsv vs Durva vs Durva+olaparib
5) Positive readout - now SOC for pMMR

21
Q

RUBY

A

1) GSK + GOG; PI Mansoor Mirza (Copenhagen University Hospital, Denmark)
2) Advanced/recurrent endo
3) Maintenance escalation
4) Obsv vs dostarlimab - now SOC for dMMR

22
Q

AtTEnd

A

1)ENGOT; PI Nicoletta Colombo (University of Milan-Bicocca)
2) Advanced/recurrent endo
3) Maintenance escalation
4) Add Atezo to chemo/maintenance - now SOC

23
Q

GY-018

A

1)NRG ; PI Ramez Eskander (UCSD)
2) Advanced/recurrent endo
3) Maintenance escalation
4) Add Pembro to chemo/maintenance - now SOC
5) Confirmed does not have tps we would need

24
Q

SIENDO

A

1) ENGOT study, PI Vikki Maker (MSK)
2) Advanced/recurrent endo
3) Maintenance escalation
4) Add Selinexor to maintenance

25
Q

LEAP-001

A

1) PI Vikki Maker (MSK)
2) Advanced/recurrent endo
3) Maintenance escalation
4) Lenvatinib + Pembro for maintenance
5) failed trial

26
Q

Endo Areas of Interest

A

1) Adjuvant therapy selection for early EC
2) Advanced/recurrent adjuvant/maintenance therapy escalation
3) Maintenance treatment monitoring and duration
4) Scan on MRD to identify local recurrences sooner?

27
Q

Locally advanced cervical treatment

A

1) Chemo + XRT
2) Questions on induction chemo before or consolidation chemo after
3) Add Pembro for advanced disease

28
Q

Cervical surveillance

A

1) one scan 2-4 mns post treatment then wait for clinical symptoms

29
Q

Metastatic cervical treatment

A

1) Chemo + either bev or IO (Atezo/Pembro)

30
Q

KN-A18

A

1) GOG/ENGOT study
2) Adding Pembro to CRT

31
Q

INTERLACE

A

1) GCIG study, PI
2) Adding induction chemo before chemo/xrt

32
Q

Cervical Areas of Interest

A

1) Is consolidation chemo after CRT needed?
2) Surveillance - frequently symptomatic at recurrence, can we avoid this?
3) IO treatment monitoring and switch non-responders

33
Q

Brad Monk

A

FL Cancer
PI: PRIMA

34
Q

Carol Aghajanian

A

MSK
PI: DUO-O

35
Q

Rob Coleman

A

Prev TX Oncology, CMO Vaniam Group
PI: GY-036

36
Q

Tom Herzog

A

U Cinncinati
PI: GY-036

37
Q

Isabelle Ray-Coquard

A

France
PI: PRIMA, NeoPembrOV

38
Q

Brian Slomovitz

A

U Miami
PI: KN-B21

39
Q

Shannon Westin

A

MDACC
PI: DUO-E

40
Q

Nicoletta Colombo

A

University of Milan-Bicocca
PI: AtTEnd

41
Q

Ramez Eskander

A

UCSD
PI: GY-018

42
Q

Vikki Maker

A

MSK
PI: SIENDO, LEAP-001

43
Q

Questions to Ask Providers

A

1) Have you seen recent data published in ctDNA?
2) Where do you see the most potential utility for ctDNA?
3) Did you hear about the recent Medicare approval in ovarian cancer?
4) Where would you like to see additional research for ctDNA in GYN malignancies?
5) Any biobanks or opportunity for RWE?

44
Q

Conference Schpeal!

A

1) So much excitement! Recently received Medicare coverage for ovary and planning to submit for endo.
2) Published papers in ovary and early endo, presented data on PARP and IO monitoring at SGO and working on publishing that
3) Working towards finding biobanks and sample sets to further validate in various settings
4) Interested in Maintenance decision making, monitoring and duration for both ovary and endo, go/no-go ACT decisions in early endo, surveillance, and metastatic treatment monitoring
5) Would love to talk in more detail about any of the above. What areas for ctDNA utility are you most interested in clinically and for research?

GYN (1 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2024 Bold Learning Solutions. Terms and Conditions